Avalanche Biotechnologies Escapes IPO Suit Over Eye Drug
Avalanche Biotechnologies Inc. on Thursday won dismissal in California federal court of an investor suit accusing it of misleading investors about the effectiveness of its gene therapy for vision loss before...To view the full article, register now.
Already a subscriber? Click here to view full article